Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine

Earlier research has reported cognitive deficits, especially verbal memory impairment, in people who use 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). Those between-group and abstinent-user studies have suggested dose-related memory problems and links to serotonergic markers, but interpretation is limited by confounding factors such as unknown dosing, polydrug use, lifestyle differences and the lack of experimental control. Only a few studies attempted to assess memory during intoxication, and those employed quasi-experimental designs (for example assessing users who self-administered MDMA before parties), which left open alternative explanations including sleep loss and uncontrolled substance use. Kuypers and colleagues designed a controlled experiment to test whether a single acute dose of MDMA produces immediate and/or residual memory impairment. The study used a double-blind, placebo-controlled, three-way crossover design in experienced recreational MDMA users, including an active control (methylphenidate) to probe whether any observed effects were likely dopaminergic rather than serotonergic in origin. The primary focus was on verbal memory measured during the intoxication phase (about 1.5 h post-dose) and the withdrawal phase (about 25.5 h post-dose).

The study employed a double-blind, placebo-controlled, three-way crossover design with counterbalancing. Each participant completed three treatment conditions separated by at least 14 days: placebo, 75 mg oral MDMA (powder dissolved in bitter orange syrup and orange juice), and 20 mg oral methylphenidate (pill). Testing occurred over two consecutive days within each treatment period; drugs/placebo were given on Day 1 and no drug was administered on Day 2. Eighteen healthy recreational MDMA users (nine men, nine women), aged 20–39 years (mean 26.22, SD 5.1), took part. Lifetime MDMA use ranged from less than 30 occasions in 15 participants to 60–120 occasions in three. Inclusion required prior MDMA experience, absence of psychotropic medication, good physical health and BMI between 18 and 28 kg/m2. Exclusion criteria included other substance addiction, pregnancy/lactation, cardiovascular abnormalities, excessive alcohol consumption, hypertension and history of psychiatric or neurological disorders. Medical screening included questionnaires, blood and urine tests and ECG; the protocol was approved by the relevant ethics committee and a licence was obtained for MDMA storage and administration. Before each testing day participants completed a training session and were instructed to abstain from drugs for one week before medical screening through 14 days after final testing, to avoid caffeine and alcohol for 24 h before testing and to obtain normal sleep. On test mornings participants were breath-tested for alcohol, urine-screened for common drugs and women took a pregnancy test. MDMA/methylphenidate concentrations were sampled at 1.5 h post-dose (Day 1) and 25.5 h post-dose (Day 2), with additional clinical chemistry checks 11 days after administration. Cognitive testing concentrated on verbal memory: a computerized verbal word-learning task (five immediate learning trials of 15 monosyllabic words, a 30-minute delayed free recall and a 30-minute recognition test). Other tests included a syntactic reasoning task (working memory and speed), and a computerized digit-symbol substitution task (short-term memory and psychomotor speed). Subjective measures comprised the Groninger Sleep Scale (sleep quality/quantity), the Profile of Mood States (POMS) subscales (Depression, Vigour, Tension, Fatigue, Anger) and the Hamilton Depression Rating Scale (HAM-D). Pharmacokinetic samples were analysed by LC-MS/MS with a quantification limit of 1 ng/mL. For statistical analysis the investigators used GLM univariate repeated measures in SPSS 11.5 with Treatment (3 levels) and Day (2 levels) as within-subject factors; Trial (5 levels) was included for immediate recall. Drug-versus-placebo contrasts were conducted when overall effects were significant. One missing POMS dataset in the placebo condition was imputed using the mean of the other 17 subjects.

Verbal learning and recall: Repeated-measures ANOVA on the immediate recall (IR) scores showed a significant Treatment by Day interaction (F(2,34) = 7.58; p = 0.002) and a large Trial effect reflecting learning across the five trials (F(4,68) = 214.86; p < 0.001). Drug–placebo contrasts on Day 1 indicated that MDMA impaired learning: participants recalled fewer words under MDMA than under placebo, with a mean difference summed over five trials of 4.6 words (SE 1.7; p = 0.009). There were no significant drug–placebo differences on Day 2 (withdrawal). Delayed recall (DR) also showed a Treatment by Day interaction (F(2,34) = 4.72; p = 0.016) and a Day main effect (F(1,17) = 5.36; p = 0.033). On Day 1 MDMA reduced delayed recall compared with placebo (F(1,17) = 9.91; p = 0.006), with participants remembering approximately 1.44 words fewer (SE 0.46). Relative recall (a measure of forgetting) showed effects of Day (F(1,17) = 7.30; p = 0.015) and Treatment by Day (F(2,34) = 3.43; p = 0.044); the MDMA–placebo contrast on Day 1 was nearly significant (F(1,17) = 3.5; p = 0.079), suggesting somewhat faster forgetting under MDMA. Recognition scores and recognition reaction times were not affected by Treatment or Day. Syntactic reasoning and digit-symbol: The syntactic reasoning task produced no Treatment effects; only a Day main effect was observed for reaction time of correct responses (F(1,17) = 9.63; p = 0.006), with faster responses on Day 2 (mean 92.01, SE 29.64) than Day 1. The digit-symbol substitution task showed a Day main effect (F(1,17) = 25.87; p = 0.001) with more correct encodings on Day 2 (mean 3.96, SE 0.78), but no Treatment or Treatment by Day effects. Subjective measures: Sleep quantity and quality did not differ by Treatment or Day; average sleep was 7.28 h (SE 0.19). POMS subscales showed Treatment by Day interactions for Fatigue (F(2,34) = 3.56; p = 0.039) and Vigour (F(2,34) = 6.15; p = 0.005). There were no drug–placebo differences on Day 1, but on Day 2 MDMA increased subjective fatigue (F(1,17) = 6.06; p = 0.025) and decreased vigour (F(1,17) = 8.71; p = 0.009) relative to placebo. HAM-D total scores showed a Day main effect (F(1,17) = 5.02; p = 0.039) with higher scores on Day 1 versus Day 2, but no Treatment effects indicating no signs of depression attributable to MDMA in this sample. Pharmacokinetics: Mean plasma MDMA concentration was 113.4 ng/mL (±37.4) at 1.5 h (Day 1) and 11.6 ng/mL (±9.3) at 25.5 h (Day 2). MDA averaged 2.9 ng/mL (±0.9) on Day 1 and 2.1 ng/mL (±1.2) on Day 2. Ritalinic acid concentrations averaged 95.9 ng/mL (±78.4) on Day 1 and 22.9 ng/mL (±7) on Day 2. Methylphenidate produced no detectable effects on memory or mood measures.

Kuypers and colleagues interpret their findings as showing that a single 75 mg dose of MDMA produces transient impairments of verbal memory during the acute intoxication phase but not during the withdrawal phase the following day. Specifically, MDMA reduced the total number of words learned across five immediate recall trials and lowered delayed recall after a 30-minute retention interval; recognition memory remained intact. The pattern—reduced immediate and delayed recall with normal recognition—resembles memory deficits reported in previous studies of abstinent MDMA users, which the authors suggest may point to overlapping neuropharmacological mechanisms. The study team argues that the lack of residual memory impairment 25.5 h post-dose indicates a single dose does not produce permanent memory damage. They also note that subjective mood changes during withdrawal were limited to increased fatigue and decreased vigour, with no evidence of depressive symptoms on the HAM-D or POMS. The absence of memory effects after methylphenidate led the investigators to attribute MDMA-induced memory impairment to serotonergic rather than dopaminergic mechanisms. Several possible serotonergic mechanisms are discussed. The authors outline a two-phase pattern of serotonin change reported in animal studies—an acute reversible depletion within the first few hours after MDMA and a later, longer-lasting depletion—and suggest that transient 5HT reductions or receptor-mediated effects might underlie the intoxication-phase memory deficit. They discuss evidence implicating postsynaptic 5HT1A and 5HT2 receptors in hippocampal learning and memory, noting that MDMA increases 5HT release and has some affinity at 5HT2A receptors, which might plausibly impair learning and delayed recall. The investigators acknowledge uncertainty about the exact mechanism and note that manipulations such as tryptophan depletion do not consistently reproduce the same profile of immediate and delayed recall impairment, indicating qualitative differences between experimental serotonin depletion and MDMA effects. They also situate their findings relative to earlier nightclub/quasi-experimental studies, emphasising that those designs were confounded by factors like sleep loss and concomitant substance use. Overall, the authors conclude that acute MDMA causes transient verbal memory impairment during intoxication but that a single dose did not produce measurable residual memory deficits the next day.